{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:58:51Z","timestamp":1780520331050,"version":"3.54.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.canlet.2010.12.002","type":"journal-article","created":{"date-parts":[[2010,12,29]],"date-time":"2010-12-29T09:26:53Z","timestamp":1293614813000},"page":"106-112","source":"Crossref","is-referenced-by-count":38,"title":["HPV prophylactic vaccination: The first years and what to expect from now"],"prefix":"10.1016","volume":"305","author":[{"given":"Luisa Lina","family":"Villa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.canlet.2010.12.002_b0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.bjc.6600688","article-title":"Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis","volume":"88","author":"Clifford","year":"2003","journal-title":"Br. J. Cancer"},{"issue":"Suppl. 10","key":"10.1016\/j.canlet.2010.12.002_b0010","doi-asserted-by":"crossref","first-page":"K17","DOI":"10.1016\/j.vaccine.2008.06.021","article-title":"Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions","volume":"26","author":"Giuliano","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2010.12.002_b0015","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1128\/JCM.37.10.3316-3322.1999","article-title":"Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients","volume":"37","author":"Brown","year":"1999","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.canlet.2010.12.002_b0020","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/00020840-200312000-00005","article-title":"Overview of recurrent respiratory papillomatosis","volume":"11","author":"Wiatrak","year":"2003","journal-title":"Curr. Opin. Otolaryngol. Head Neck Surg."},{"issue":"Suppl. 10","key":"10.1016\/j.canlet.2010.12.002_b0025","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1016\/j.vaccine.2008.05.064","article-title":"Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia","volume":"26","author":"Bosch","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2010.12.002_b0030","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/jnci\/djg037","article-title":"Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia","volume":"95","author":"Schlecht","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2010.12.002_b0035","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1056\/NEJMoa065497","article-title":"Case-control study of human papillomavirus and oropharyngeal cancer","volume":"356","author":"D\u2019Souza","year":"2007","journal-title":"New Engl. J. Med."},{"issue":"8","key":"10.1016\/j.canlet.2010.12.002_b0040","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1158\/1055-9965.EPI-08-0151","article-title":"The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States","volume":"17","author":"Giuliano","year":"2008","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"Suppl. 2","key":"10.1016\/j.canlet.2010.12.002_b0045","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S1201-9712(07)60017-4","article-title":"Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine","author":"Villa","year":"2007","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.canlet.2010.12.002_b0050","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2010.12.002_b0055","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol."},{"issue":"19","key":"10.1016\/j.canlet.2010.12.002_b0060","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"Future II Study Group","year":"2007","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.canlet.2010.12.002_b0065","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","article-title":"Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials","volume":"369","author":"Ault","year":"2007","journal-title":"Lancet"},{"issue":"9518","key":"10.1016\/j.canlet.2010.12.002_b0070","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"HPV vaccine study group sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"M Harper","year":"2006","journal-title":"Lancet"},{"issue":"9574","key":"10.1016\/j.canlet.2010.12.002_b0075","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","article-title":"Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials","volume":"369","author":"Joura","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2010.12.002_b0080","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.canlet.2010.12.002_b0085","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"issue":"2 Suppl. 1","key":"10.1016\/j.canlet.2010.12.002_b0090","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ygyno.2007.08.059","article-title":"Human papillomavirus vaccines and the potential for cross-protection between related HPV types","volume":"107","author":"Ault","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"27 Suppl. 1","key":"10.1016\/j.canlet.2010.12.002_b0095","doi-asserted-by":"crossref","first-page":"A46","DOI":"10.1016\/j.vaccine.2008.10.085","article-title":"Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence","volume":"29","author":"Bonanni","year":"2009","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.canlet.2010.12.002_b0100","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1086\/520654","article-title":"Quadrivalent human papillomavirus vaccine","volume":"45","author":"Barr","year":"2007","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"10.1016\/j.canlet.2010.12.002_b0105","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/jama.2009.1201","article-title":"Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine","volume":"302","author":"Slade","year":"2009","journal-title":"JAMA"},{"issue":"27\u201328","key":"10.1016\/j.canlet.2010.12.002_b0110","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"issue":"3 Suppl. 1","key":"10.1016\/j.canlet.2010.12.002_b0115","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ygyno.2008.05.036","article-title":"Immune response to human papillomavirus after prophylactic vaccination withAS04-adjuvanted HPV-16\/18 vaccine: improving upon nature","volume":"110","author":"Schwarz","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"26","key":"10.1016\/j.canlet.2010.12.002_b0120","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1016\/j.vaccine.2007.03.049","article-title":"Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6\/11\/16\/18 L1 virus-like particle (VLP) vaccine","volume":"25","author":"Olsson","year":"2007","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.canlet.2010.12.002_b0125","first-page":"459","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br. J. Cancer"},{"issue":"S3","key":"10.1016\/j.canlet.2010.12.002_b0130","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.vaccine.2006.05.109","article-title":"Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries","volume":"24","author":"Lehtinen","year":"2006","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.canlet.2010.12.002_b0135","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.inf.0000253970.29190.5a","article-title":"18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial","volume":"26","author":"Reisinger","year":"2007","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"6","key":"10.1016\/j.canlet.2010.12.002_b0140","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jadohealth.2007.02.015","article-title":"Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant","volume":"40","author":"Pedersen","year":"2007","journal-title":"J. Adolesc. Health"},{"issue":"9679","key":"10.1016\/j.canlet.2010.12.002_b0145","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(09)60691-7","article-title":"Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24\u201345 years: a randomised, double-blind trial","volume":"373","author":"Mu\u00f1oz","year":"2009","journal-title":"Lancet"},{"issue":"3 Suppl.","key":"10.1016\/j.canlet.2010.12.002_b0150","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.ygyno.2009.09.021","article-title":"HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives","volume":"115","author":"Castellsagu\u00e9","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2010.12.002_b0155","doi-asserted-by":"crossref","DOI":"10.4161\/hv.5.10.9515","article-title":"Evaluation of quadrivalent HPV 6\/11\/16\/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection","volume":"5","author":"Olsson","year":"2009","journal-title":"Hum. Vaccin."},{"issue":"3","key":"10.1016\/j.canlet.2010.12.002_b0160","first-page":"131","article-title":"Progress in the research on HPV vaccination: updates from the 25th international papillomavirus conference in Malmo, Sweden, 2009","volume":"50","author":"Bonanni","year":"2009","journal-title":"J. Prev. Med. Hyg."},{"key":"10.1016\/j.canlet.2010.12.002_b0165","unstructured":"J. Palefski, Oral Presentation, Eurogin, Monaco, Feb 2010"},{"issue":"7","key":"10.1016\/j.canlet.2010.12.002_b0170","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/sti.2009.037788","article-title":"Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women","volume":"85","author":"Fairley","year":"2009","journal-title":"Sex. Transm. Infect."},{"issue":"Suppl. 1","key":"10.1016\/j.canlet.2010.12.002_b0175","doi-asserted-by":"crossref","first-page":"A24","DOI":"10.1016\/j.vaccine.2007.11.059","article-title":"Monitoring HPV vaccination","author":"Stanley","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2010.12.002_b0180","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2249.2007.03384.x","article-title":"Translational mini-review series on vaccines: monitoring of human papillomavirus vaccination","volume":"148","author":"Dillner","year":"2007","journal-title":"Clin. Exp. Immunol."},{"issue":"6","key":"10.1016\/j.canlet.2010.12.002_b0185","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/ijc.21515","article-title":"Collaborative study participants, results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses","volume":"118","author":"Ferguson","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"S3","key":"10.1016\/j.canlet.2010.12.002_b0190","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.vaccine.2006.05.061","article-title":"Issues in planning cervical cancer screening in the era of HPV vaccination","volume":"24","author":"Franco","year":"2006","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.canlet.2010.12.002_b0195","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.vaccine.2006.05.120","article-title":"HPV in immunocompromised women and men","volume":"24","author":"Palefsky","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2010.12.002_b0200","unstructured":"A. Weinberg et al., Safety and immunogenicity of a quadrivalent vaccine to prevent human papillomavirus (HPV) in HIV-infected children: IMPAACT P1047. Poster 619a Presented at the 15th Conference on Retroviral and Opportunistic Infections, Boston, USA."},{"issue":"52","key":"10.1016\/j.canlet.2010.12.002_b0205","doi-asserted-by":"crossref","first-page":"7236","DOI":"10.1016\/j.vaccine.2009.05.019","article-title":"WHO position on HPV vaccines","volume":"27","year":"2009","journal-title":"Vaccine"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383510005525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383510005525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T02:12:33Z","timestamp":1592187153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383510005525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0304383510005525"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2010.12.002","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}